September 12th 2024
The trial showcased the continued efficacy of apremilast, with 2-year data on the forefront.
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Dermalorian™ Webinar Series on Moderate to Severe Atopic Dermatitis
November 21, 2024 - December 5, 2024
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
New pediatric research beacon for larger studies
December 1st 2005Harrison Hot Springs, British Columbia — According to Robert Sidbury, M.D., two of the most important pediatric studies published this year investigated the alleged connection between isotretinoin and depression, thoughts of suicide and even suicide itself among some teenage users being treated for acne.
Patient instruction essential to effective acne medication application
November 1st 2005Proper application consists of placing a "fingertip unit" of medication at each of 10 spots on the face — two on the mid-forehead (left and right), one each on the tip of the nose and chin, two spaced across each cheek, and one on each side of thelower face at a location that is approximately mid-distance between the spots on the cheek.
New bankruptcy laws make old asset protection planning obsolete
November 1st 2005What effect, if any, has the new bankruptcy act had on physician's asset protection plans? In short, the answer is "a significant one." In this article, we will explain exactly what this effect has been and why it is so important for all physicians to re-examine their planning because of it.
FDA to Review Diaper-Dermatitis Ointment for Approval
November 1st 2005Washington--The Food and Drug Administration has notified Barrier Therapeutics that it has deemed as a complete response the company's submission to address the FDA's May "not approvable" letter for Zimycan, a diaper-dermatitis ointment that contains miconazole nitrate.